Transcript 36pt Trebuchet MS Bold
General Overview to the CTD and Module 1
Gudrun Dora Gisladottir Director Regulatory Affairs
Using CTD format
• •
Actavis group hf
• • •
International generic pharmaceutical company First EU submissions in early ’90’s
• Captopril first MRP 1994
Finalize 10 – 20 new development projects per year CTD format in EU since 2002 First eCTD submitted
Using CTD format
• • •
Already reformatted most of the “older” dossiers
• New markets • Variations • Renewals
Mixed format >70 dossiers in CTD format
CTD Format What is it?
Common Technical Document (CTD) is;
• •
A common format for presentation of technical documentation according to agreed international standards Built around ICH and a mixture of FDA/EU/Japanese standards It is not;
•
A single file that will meet the needs of authorities – regional requirements and guidelines still apply where not covered by ICH
CTD Format Why use it?
• • • • • • • •
It is a regulatory requirement in EU!
Logical order, representing sequential development path.
User friendly review Theoretically possible to create “global dossier”!
Queries and deficiency letters simpler to answer Agreement on defined terms assists the harmonization process between regions Electronic submission should be easier to prepare Encourages implementation of ICH guidelines
CTD – Is it worth it?
From the Industry’s perspective;
• •
YES! For new submissions For dossiers already compiled in the NtA format, probably NO!
• Mixed format • Variations
Authorities
•
?
CTD outline of structure
•
The CTD is organized into five modules
• •
Administrative, regional or national information is provided in Module 1 – content specified by individual authorities
• EU application form, the proposed SmPC, the labelling and package leaflet
Modules 2, 3, 4 and 5 are intended to be common for all regions
Module 2 Diagrammatic Representation of the Organization of the ICH CTD Common Technical Document Module 1
Regional Administrative Information 1 1.1 Submission T of C
Not part of the CTD
Quality Overall Summary 2.3
Module 3
Quality 3 3.1 T of C CTD Table of Contents 2.1 CTD Introduction 2.2 Nonclinical Overview 2.4 Nonclinical Written and Tabulated Summaries 2.6 Clinical Overview 2.5 Clinical Summary 2.7
Module 4
Nonclinical Study Reports 4 4.1 T of C
Module 5
Clinical Study Reports 5 5.1 T of C
CTD
CTD outline of structure
• • •
Chemical, Pharmaceutical and Biological documentation is provided in the Quality Overall Summary from Module 2 and by Module 3 (previously Part II) Toxicological and Pharmaceutical Documentation is provided in the Non-clinical Written Summary from Module 2 and by the Non-clinical Study Reports in Module 4 (part III) The clinical documentation is provided in the Clinical Written Summary form Module 2 and in the Clinical Study Reports Module 5 (part IV)
CTD Module 2 Generic applications
Module 2 contains high level summaries
•
Quality Overall Summary, QOS (Module 2.3)
•
Non clinical Overview / Summary, NCOS (Module 2.4)
•
Clinical Overview / Summary COS (Module 2.5)
CTD Module 2
•
EU legal requirement that dossiers should be prepared by suitably qualified and experienced experts
•
Though CTD format does not mention expert reports the content is expected to be given in the QOS, NCOS, COS
•
Experts have to sign and give their CV
CTD Module 3
• • •
Replaces Part II
• See correlation table for full details
Splits Drug Substance from Drug Product
• S (DMF) and P
Follows logic of Development process
Module 3 Drug Master File (DMF)
• • •
What is a DMF?
DMF is divided into two parts – the applicants part “open” and the drug substance manufacturers part “closed” part (confidential only to be reviewed by authorities) Applicant’s part provides sufficient information to allow evaluation of the suitability of the specification to control the quality
• • • • Brief information on manufacturing Information on impurities arising from manufacturing method Information on degradation products Information on toxicity of impurities where applicable
Module 3 Drug Master File (DMF)
• • •
Drug substance manufacturer gives permission to the authorities to access data in closed part as “Letter of Access” (LoA) Applicant submits the open part Use CTD format
3.2.S.1
3.2.S.1.1
3.2.S.1.2
3.2.S.1.3 3.2.S.2
3.2.S.2.1
3.2.S.2.2
3.2.S.3
3.2.S.3.1
3.2.S.3.2
3.2.S.4
3.2.S.4.1
3.2.S.4.2
3.2.S.4.3
3.2.S.4.4
3.2.S.4.5
3.2.S.5
3.2.S.6
3.2.S.7
Module 3 Drug Master File (DMF)
General Information Nomenclature Structure General Properties Manufacture Manufacturer(s) Description of Manufacturing Process and Process Controls Control of Materials Elucidation of Structure and Other Characteristics Impurities Control of Drug Substance Specification Analytical Procedure Validation of Analytical Procedures Batch Analyses Justification of Specification Reference standards or Materials Container Closure System Stability
Module 3 Certificate of Suitability
• • • • •
Used for pharmacoepial substances (actives or excipients) Documentation submitted directly to Ph. Eur. Secretariat Avoid repeated assessment of same DMF by various authorities Certification scheme includes requirements for a declaration concerning GMP and willingness to be inspected Applicant includes the Certificate of Suitability (CoS) in the dossier
3.2.P.1
3.2.P.2
3.2.P.2.4
3.2.P.3
3.2.P.3.1 3.2.P.3.2
3.2.P.3.3
3.2.P.3.4
3.2.P.3.5
CTD Module 3 Drug Product
Description and Composition of the Drug Product Pharmaceutical Development Controls and Critical Steps Manufacture Manufacturer(s) Batch Formula Description of Manufacturing Process and Process Controls Controls of Critical Steps and Intermediates Process validation and/or evaluation
3.2.P.4
3.2.P.4.5
3.2.P.4.6
3.2.P.5
3.2.P.5.1
3.2.P.5.2
3.2.P.5.3
3.2.P.5.4
3.2.P.5.5
3.2.P.5.6
3.2.P.6
3.2.P.7
3.2.P.8
CTD Module 3 Drug Product
Control of excipients Excipients of Human or Animal Origin Novel Excipients Control of Drug Product Specification(s) Analytical Procedures Validation of Analytical Procedures Batch Analyses Characterisation of Impurities Justification of Specification(s) Reference Standards or Materials Container Closure System Stability
Module 4
•
For Generic Application
• Only literature review • EU authorities – different opinion on whether this is needed in the application
Module 5
For a generic application
• • • •
Reports from literature BE report Justification and discussion regarding design and results 5.3.2 comparative BA and bioequivalence study
Common Technical Document Detailed Structure
Fine details of requirements for each module:
•
Revised Notice to Applicants Volume 2B published in June 2004
•
Sections in Part R; Regional information
•
References are to ICH and CPMP guidelines
•
Various Q and A documents available
CTD Presentations General Considerations
• • • • •
Throughout the display of information should be unambiguous and transparent, to facilitate the review Use margins that allow the document to be printed on A4 paper The left hand margin should be sufficiently large that information is not obscured through binding Font sizes for text and tables should be of style and size that are large enough to be easily legible even after photocopying Acronyms and abbreviations should be defined the first time they are used in each module
CTD Presentation Organisation of sections
• • • •
ICH Guideline M4: CTD for the registration of Pharmaceuticals for human use; organisation of common technical document implemented 2003 – incorporates “Granularity Document” Defines how to split sections down into separate documents Prepares the way for electronic submission The Granularity guideline defines “Document” and states that each document should be paginated separately (electronic file)
CTD Presentation Organisation of sections Practical experience
In deciding whether one or more documents or files are appropriate, it should be considered that once a
particular approach
has been adopted the
same approach
should be used
the life of the dossier
intention that replacement information is changed
throughout
since it is the documents/files be provided when
CTD Presentation Organisation of sections
• • • •
For Module 3 the situation can be very complicated For a drug product containing more than one drug substance the information requested for part “S” should be provided in its entirety for each drug substance More than one Drug Substance supplier More than one manufacturing site for the finished product
Electronic Dossiers eCTD
• • •
CTD makes it possible to agree upon standard for an electronic submission XML backbone plus PDF files Are authorities ready?
Global Dossier Major Challenges
• • • •
Level of details (U.S.A) e.g. description of synthesis, in process controls, raw materials, container Compendial differences – not all monographs are harmonized (USP, Ph. Eur.) GMP issues Stability, US requires site specific data, 3 months v.s. 6 months Plus the BE study!
Module 1 Regional Information - EU
•
Table of Content Typical Module 1 - Actavis
1.1 Comprehensive Table of Contents 1.2 Application Form Annexed Documents 6.3 Proof of establishment of MA holder 6.4 Letter of authorisation for communication 6.5 Curriculum Vitae of the Qualified Person for Pharmacovigilance 6.6 Manufacturing Authorisation 6.7 Justification for more than one manufacturer responsible for batch release 6.8 Flow-chart indicating the different sites involved in the manufacturing process 6.10 Letter of Access to DMF 6.11 Copy of written confirmation of the AIM 6.15 Copy of Marketing Authorization(s) required under Directive 2001/83/EC Proof of first Authorisation of essential similar medical product in EU 6.22 Declaration from the Qualified Person of the manufacturing authorisation holder
Table of Content Typical Module 1 – Actavis cont.
1.3
1.4 1.5.2 Summary of Product Characteristics, Labelling and Package Leaflet.
1.3.1 SPC 1.3.2 Labelling 1.3.3 PIL 1.3.4 Readability Justification Information about the Experts Information for abridged applications
Module 1
The application form is to be used for an application for a marketing authorisation of a medicinal product for human use submitted to (a) the European Agency for the Evaluation of Medicinal Products under the
centralised procedure
or (b) a Member State (as well as Iceland, Lichtenstein and Norway) under either a
national, mutual recognition procedure
or
decentralised procedure
.
Application Form EU - Region
1.
Type of application 1.1 This application concerns 1.2 Orphan medicinal product designation 1.3 Referring to Annex II of Regulations (EC) N ° 1084/2003 or1085/2003 [1] 2.
Marketing authorisation application particulars 2.1 Name(s) and ATC code 2.2 Strength, pharmaceutical form, route of administration, container and pack sizes 2.3 Legal status 2.4 Marketing authorisation holder, Contact persons, Company 2.5 Manufacturers 2.6 Qualitative and quantitative composition
Application Form EU - Region
3.
4.
Scientific advice Paediatric Development Programme 5.
Other marketing authorisation applications Appended documents 6.1 Proof of payment 6.2 Informed consent letter of marketing authorisation holder of authorised medicinal product.
6.3 Proof of establishment of the applicant in the EEA.
6.4 Letter of authorisation for communication on behalf of the applicant/MAH 6.5 Curriculum Vitae of the Qualified Person for Pharmacovigilance 6.6 Manufacturing Authorisation required under Article 40 of Directive 2001/83/EC (or equivalent, outside of the EEA where MRA or other Community arrangements apply). A reference to EudraGMP will suffice when available.
6.7 Justification for more than one manufacturer responsible for batch release in the EEA
Application Form EU - Region
6.8
Flow-chart indicating all sites involved in the manufacturing process of the medicinal product or active substance (including sites involved in sampling and testing for batch release of products manufactured in third countries).
Note: ALL manufacturing and control sites mentioned throughout the whole dossier MUST be consistent regarding their names, detailed addresses and activities.
6.9
Statement (or GMP Certificate issued by an EEA inspectorate, when available) from the competent authority which carried out the inspection of the manufacturing site(s) (not older than 3 years). References to EudraGMP will suffice when available. Where applicable a summary of other GMP inspections performed in the last 2 years 6.10 Letter(s) of access to Active Substance Master File(s) or copy of Ph. Eur. Certificate(s) of suitability 6.11 Copy of written confirmation from the manufacturer of the active substance to inform the applicant in case of modification of the manufacturing process or specifications according to Annex I of Directive 2001/83/EC.
6.12 Ph. Eur. Certificate(s) of suitability for TSE 6.13 Written consent(s) of the competent authorities regarding GMO release in the environment.
Application Form EU - Region
6.14 Scientific Advice given by CHMP 6.15 Copy of Marketing Authorization(s) required under Article 8(j)-(L) of Directive 2001/83/EC in the EEA and the equivalent in third countries on request (a photocopy of the pages which give the marketing authorization number, the date of authorisation and the page which has been signed by the authorizing competent authority will suffice).
6.16 Correspondence with European Commission regarding multiple applications.
6.17 List of Mock-ups or Samples/specimens sent with the application, as appropriate (see Notice to Applicants, volume 2A, chapter 7) 6.18 Copy of the Orphan Designation Decision.
6.19 List of proposed (invented) names and marketing authorisation holders in the concerned member states 6.20 Copy of EMEA certificate for a Vaccine Antigen Master File (VAMF) 6.21 Copy of EMEA certificate for a Plasma Master File (PMF) 6.22 For each active substance, attach a declaration from the Qualified Person of the manufacturing authorisation holder in Section 2.5.1 and from the Qualified Person of each of the manufacturing authorisation holders (i.e. located in EEA) listed in Section 2.5.2 where the active substance is used as a starting material that the active substance manufacturer(s) referred to in Section 2.5.3 operate in compliance with the detailed guidelines on good manufacturing practice for starting materials. This does not apply to Blood or blood components.
Module 1 New Requirements
•
For each active substance, attach a declaration from the Qualified Person of the manufacturing authorisation holder in Section 2.5.1 and from the Qualified Person of each of the manufacturing authorisation holders (i.e. located in EEA) listed in Section 2.5.2 where the active substance is used as a starting material that the active substance manufacturer(s) referred to in Section 2.5.3 operate in compliance with the detailed guidelines on good manufacturing practice for starting materials. This does not apply to Blood or blood components.
Module 1 New Requirements
•
Readability testing PIL
• • • •
Typical testing
Participants (preferably patients) read the PIL Two rounds of interviews (10 in the first and 10-20 in the second round) 1.
2.
3.
Locate the information in the PIL Understand it Know how to act on it Might have to revise the PIL based on the outcome
Type of MA Application
• • • •
National
• Single member state (MS) • Older well established products
Mutual Recognition
• Approved in one MS, Reference Member State (RMS) • Multiple identical MAs in many Concerned Member States (CMS) • Harmonised MA granted
Decentralised - New procedure!
• RMS and CMS • Approved in all selected MS at the same time
Centralised
• • • Mainly biotech products Single MA in all MS MA issued bye EMEA via the commission
Variations Maintaining the MAA
• • •
Activities post approval
• • • Changing the way the product is made Additional manufacturing site Additional Drug Substance supplier– Dual sourcing policy
Improve safety
• • New indications Additional warnings
Improve quality
• New stability results from commercial batches
Variations Maintaining the MAA
New EU regulation regarding variations since Oct 2003
• • • •
Type IA (minor) Type IB (minor) 14 days 30 days Type II (major) 60- 90 days Fundamental Variations (New application)
•
Urgent safety restriction
Variations Maintaining the MAA
•
Type IA (notification) “tell and do”
• •
Type IB (notification) “tell, wait and do” Type II (approval) “tell and wait” RMS is responsible for processing Type IA and IB on behalf of CMS
Variations Maintaining the MAA
For each Type I variation, the guideline indicates;
• Details of the change • • • Conditions/remarks attached to the change Documentation to be supplied 46 types of variations
A variation is only regarded as Type I if the conditions are met AND the relevant supporting data are provided The variation will be considered Type II if either of these conditions are not met